| Ytd | -8.65% | |
| 1y | -49.68% |
| Open | 3.20 | Prev Close | 3.14 | Low | 3.08 | High | 3.28 | Mkt Cap | 150.63M |
| Vol | 452.04K | Avg Vol | 934.55K | EPS | -0.53 | P/E | N/A | Forward P/E | -124.75 |
| Beta | 2.02 | Short Ratio | 7.78 | Inst. Own | 40.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 3.94 | 200-d Avg | 3.89 | 1yr Est | 12.00 |
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the
B. Riley Securities analyst William Woods maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers th
LifeMD, Inc. (LFMD) Q2 2026 Earnings Call Transcript
LifeMD NASDAQ: LFMD reported second-quarter revenue of $47.3 million, within its prior guidance rang
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Est
UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue
LifeMD (NASDAQ:LFMD) lowers FY2026 sales outlook from $220.000 million-$230.000 million to $205.500
LifeMD (NASDAQ:LFMD) reported quarterly losses of $(0.16) per share which missed the analyst consens
LifeMD (NASDAQ: LFMD - Get Free Report) and Ryman Healthcare (OTCMKTS:RYHTY - Get Free Report) are b
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtu
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient
LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and specialty care today ann
Landmark agreement between a leading virtual care company and a pharmaceutical manufacturer establis
NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading direct-to-patient
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading platform for virtu
LifeMD, Inc. (LFMD) Q1 2026 Earnings Call Transcript
LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Esti
LifeMD (NASDAQ:LFMD) affirms FY2026 sales outlook from $220.000 million-$230.000 million to $220.000
LifeMD (NASDAQ:LFMD) reported quarterly losses of $(0.20) per share which beat the analyst consensus
First quarter 2026 revenue of $50.2 million and adjusted EBITDA loss of $4.5 million, above and in l
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virt
Hims & Hers stock falls as Amazon launches a weight loss program with integrated care, pricing o
LifeMD (LFMD) was a big mover last session on higher-than-average trading volume. The latest trend i
LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced tha
LifeMD expands its weight management program with the addition of Foundayo, offering eligible patien
Novo Nordisk launches the first Wegovy subscription program. Save on injections and pills through Ro
LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the
Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD's colla
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virt
https://www.sec.gov/Archives/edgar/data/948320/0001493152-26-011228-index.html
LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the
Wall Street analysts upgraded PennyMac, LifeMD, Upstart, Circle Internet, and Rocket Companies. See
Mizuho analyst Steven Valiquette upgrades LifeMD (NASDAQ:LFMD) from Neutral to Outperform and rai
Freedom Capital Markets analyst Ilya Zubkov maintains LifeMD (NASDAQ:LFMD) with a Buy and raises
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and raises the
LifeMD (NASDAQ:LFMD) reported quarterly losses of $(0.04) per share which beat the analyst consensus
Novo Nordisk launches Wegovy weight loss pill in the US, showing up to 17% weight loss, with prices
Benzinga examined the prospects for many investors' favorite stocks over the last week — here
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the
Keybanc analyst Steve Dechert maintains LifeMD (NASDAQ:LFMD) with a Overweight and lowers the pr
Mizuho analyst Steven Valiquette maintains LifeMD (NASDAQ:LFMD) with a Neutral and lowers the pri